By applying this approach to two gene expression datasets followed by validation at the protein level, we identified NFAT5 as a novel biomarker that potentially might be developed into clinical assays to improve IBC classification into molecularly distinct phenotype. This evidence concerns the gene NFAT5 and inflammatory breast carcinoma.